What do systematic reviews say?

Oral vs IV followed by oral (11 days) therapy

• Antibiotics for acute pyelonephritis in children 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 808 participants
  Moderate

Oral vs IV followed by oral (11 days) therapy

Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: all included children… compared with IV followed by oral (11 days) therapy (moderate certainty).

• Antibiotics for acute pyelonephritis in children 2014 · Cochrane Headline outcomes only
  RR 0.82 [0.59, 1.12]
  4 studies · 943 participants
  Moderate

Oral vs IV followed by oral (11 days) therapy

Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: children with renal… compared with IV followed by oral (11 days) therapy (moderate certainty).

• Antibiotics for acute pyelonephritis in children 2014 · Cochrane Headline outcomes only
  RR 0.79 [0.61, 1.03]
  4 studies · 681 participants
  Moderate

Intermittent oral vs oral calcitriol

Intermittent oral showed no clear difference in fall in PTH compared with daily oral calcitriol (moderate certainty).

• Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
  RR 0.88 [0.65, 1.19]
  1 study · 59 participants
  Moderate
• Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 83 participants
  Moderate

Intermittent oral vs oral calcitriol

• Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 83 participants
  Moderate

Intermittent oral vs oral calcitriol

• Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 80 participants
  Moderate

Intermittent oral vs oral calcitriol

• Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 59 participants
  Low

Intermittent oral vs oral calcitriol

• Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Intravenous ± oral steroids vs oral steroids alone

It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.5 [0.05, 4.75]
  1 study · 22 participants
  Very low

Intravenous ± oral steroids vs oral steroids alone

It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.13 [0.15, 0.4]
  1 study · 18 participants
  Very low

Intravenous ± oral steroids vs oral steroids alone

It is very uncertain whether intravenous ± oral steroids changes complete remission Time frame: 2 to 28 months compared with oral steroids alone (very low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 1.76 [0.17, 18.32]
  2 studies · 35 participants
  Very low

Intravenous ± oral steroids vs oral steroids alone

The review found no eligible studies for this question.

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intravenous ± oral steroids vs oral steroids alone

It is very uncertain whether intravenous ± oral steroids changes relapse during compared with oral steroids alone (very low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 1.18 [0.65, 2.15]
  1 study · 19 participants
  Very low

Mycophenolate sodium + oral steroids vs oral steroids alone

Mycophenolate sodium + oral steroids showed no clear difference in complete remission Time frame: 4 weeks compared with oral steroids alone (moderate certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 1.12 [0.84, 1.5]
  1 study · 114 participants
  Moderate
• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.84, 1.38]
  2 studies · 134 participants
  Moderate

Mycophenolate sodium + oral steroids vs oral steroids alone

Mycophenolate sodium + oral steroids showed no clear difference in complete or partial remission Time frame: 24 weeks to end of treatment compared with oral steroids alone (moderate certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.92 [0.75, 1.12]
  2 studies · 134 participants
  Moderate

Mycophenolate sodium + oral steroids vs oral steroids alone

Mycophenolate sodium + oral steroids showed no clear difference in relapse Time frame: 24 weeks compared with oral steroids alone (low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.43 [0.08, 2.25]
  2 studies · 80 participants
  Low

Mycophenolate sodium + oral steroids vs oral steroids alone

Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.67 [0.12, 3.84]
  1 study · 116 participants
  Low

Mycophenolate sodium + oral steroids vs oral steroids alone

Mycophenolate sodium + oral steroids showed no clear difference in adverse events: acute kidney injury compared with oral steroids alone (low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.5 [0.05, 5.36]
  1 study · 116 participants
  Low

Mycophenolate sodium + oral steroids vs oral steroids alone

Mycophenolate sodium + oral steroids showed no clear difference in adverse events: new‐onset glucose intolerance compared with oral steroids alone (low certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 4.08]
  2 studies · 136 participants
  Low

Calcineurin inhibitors ± oral steroids vs oral steroids alone

Calcineurin inhibitors ± oral steroids showed no clear difference in complete remission Time frame: 2 to 6 months compared with oral steroids alone (moderate certainty).

• Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes only
  RR 0.99 [0.93, 1.05]
  8 studies · 492 participants
  Moderate